GSK Halts Development of Cough Drug After Mixed Phase 3 Trial Results
Product·2 articles across 2 outlets
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
GSK Plc halted development of an experimental drug for chronic cough, saying it was “unlikely to transform patient care.”
GSK has ended development of camlipixant in chronic cough after delivering mixed phase 3 data, dealing a major blow to a potential blockbuster that analysts saw as the key 2026 catalyst for the drugmaker.
GSK
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“GSK Plc halted development of an experimental drug for chronic cough, saying it was “unlikely to transform patient care.””
Bloomberg — GSK Scraps Chronic Cough Drug After Mixed Trial Results“GSK has ended development of camlipixant in chronic cough after delivering mixed phase 3 data, dealing a major blow to a potential blockbuster that analysts saw as the key 2026 catalyst for the drugmaker.”
fierce biotech — <a href="/biotech/gsk-axes-key-cough-drug-candidate-after-phase-3-data-disappoint" hreflang="en">GSK axes key cough drug candidate after phase 3 data end blockbuster hopes</a>